摘要
在过去的几年里,在肿瘤细胞中识别新的治疗靶点方面的显著进展导致了新的抗肿瘤药物支架的发现和开发。肿瘤细胞表观遗传调控的探索和开发对医药和学术生物医学文献都具有重要意义。表观遗传机制对于组织特异性基因表达的正常发育和维持是必不可少的。破坏表观遗传过程以根除肿瘤细胞是最有前途的癌症控制干预措施之一。Polycomb抑制复合物2(PRC2),一种将组蛋白H3的赖氨酸27甲基化以促进转录沉默的复合物,参与协调细胞中的重要途径。PRC2在许多恶性肿瘤中都被发现过表达,使其成为抗癌治疗的主要靶点。尽管其分子机制很清楚,但其亚基的高激活和耐药突变已成为一个值得讨论的问题。这篇综述概述了目前对PRC2在活性复合物形成中的成分的理解,并评估了它们作为一个有前途的癌症治疗靶点的潜力。我们还回顾了在人类癌症范围内的PRC2成分突变的影响。最后,我们讨论了目前针对PRC2复合物的治疗药物设计的一些挑战。
关键词: 癌症,表观遗传学,PRC2,组蛋白甲基化,药物开发,治疗性。
Current Drug Targets
Title:New Framework for the Discovery of PRC2 Inhibitors: Epigenetic Drugs
Volume: 22 Issue: 11
关键词: 癌症,表观遗传学,PRC2,组蛋白甲基化,药物开发,治疗性。
摘要: Over the past several years, remarkable progress towards the recognition of new therapeutic targets in tumor cells has led to the discovery and development of newer scaffolds of anti-tumor drugs. The exploration and exploitation of epigenetic regulation in tumor cells are of immense importance to both the pharmaceutical and academic biomedical literatures. Epigenetic mechanisms are indispensable for the normal development and maintenance of tissue-specific gene expression. Disruption of epigenetic processes to eradicate tumor cells is among the most promising intervention for cancer control. Polycomb repressive complex 2 (PRC2), a complex that methylates lysine 27 of histone H3 to promote transcriptional silencing, is involved in orchestrating significant pathways in a cell. Overexpression of PRC2 has been found in a number of cancerous malignancies, making it a major target for anti-cancer therapy. Despite its well-understood molecular mechanism, hyperactivation and drug resistance mutations in its subunits have become a matter of discussion. This review outlines the current understanding of the components of PRC2 in active complex formation and assesses their potential as a promising therapeutic target for cancer therapy. We also review the effects of mutations in the PRC2 components, in the purview of human cancers. Finally, we discuss some of the current challenges for therapeutic drug designs targeting the PRC2 complex.
Export Options
About this article
Cite this article as:
New Framework for the Discovery of PRC2 Inhibitors: Epigenetic Drugs, Current Drug Targets 2021; 22 (11) . https://dx.doi.org/10.2174/1389450122666210215111744
DOI https://dx.doi.org/10.2174/1389450122666210215111744 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DNA Methylation as a Target of Epigenetic Therapeutics in Cancer
Anti-Cancer Agents in Medicinal Chemistry Targeted and Immune-Based Therapies for Acute Myeloid Leukemia: Inflammatory Signaling and Multiple Post-Translational Modifications
Current Medicinal Chemistry Mesenchymal Stromal Cells Uptake and Release Paclitaxel without Reducing its Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy
Current Pharmaceutical Design Nucleoside Transport as a Potential Target for Chemotherapy in Malaria
Current Pharmaceutical Design New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension
Current Medicinal Chemistry Review of Procedures Used for the Extraction of Anti-Cancer Compounds from Tropical Plants
Anti-Cancer Agents in Medicinal Chemistry Cardiovascular Biology of Interleukin-6
Current Pharmaceutical Design Paraneoplastic Pemphigus: Autoimmune-Cancer Nexus in the Skin
Anti-Cancer Agents in Medicinal Chemistry MicroRNA-203: Tumor Suppression and Beyond
MicroRNA Reduction of Hyperproduction of Thyroid Autoantibodies in Patients without Disturbance of the Thyroid Function: New Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery A New Approach for β-cyclodextrin Conjugated Drug Delivery System in Cancer Therapy
Current Drug Delivery Molecular Docking Study, Cytotoxicity, Cell Cycle Arrest and Apoptotic Induction of Novel Chalcones Incorporating Thiadiazolyl Isoquinoline in Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry Targeting Cancer Stem Cells: Promises and Challenges
Anti-Cancer Agents in Medicinal Chemistry Targeting DNA Minor Groove by Hybrid Molecules as Anticancer Agents
Current Medicinal Chemistry The Emerging Role of Bcr-Abl-Induced Cystoskeletal Remodeling in Systemic Persistence of Leukemic Stem Cells
Current Drug Delivery GSK3 Inhibitors and Disease
Mini-Reviews in Medicinal Chemistry Structure-Based Drug Design to Overcome Drug Resistance: Challenges and Opportunities
Current Pharmaceutical Design Long Noncoding RNA GAS5: A Novel Marker Involved in Glucocorticoid Response
Current Molecular Medicine Meet Our Editorial Board Member:
Protein & Peptide Letters